尿 miR-21-5p 作为预测他达拉非治疗良性前列腺增生疗效的潜在生物标志物。
Urine miR-21-5p as a potential biomarker for predicting effectiveness of tadalafil in benign prostatic hyperplasia.
作者信息
Tanaka Tomoaki, Minami Akinori, Tashiro Kouichiro, Yoshida Naomasa, Tohda Akira, Yamakoshi Yasuo, Yasumoto Ryoji, Sugita Shozo, Nakatani Tatsuya
机构信息
Department of Urology, Osaka City University Graduate School of Medicine, Osaka, Osaka, Japan.
Department of Urology, Meijibashi Hospital, Matsubara, Osaka, Japan.
出版信息
Future Sci OA. 2018 Mar 15;4(6):FSO304. doi: 10.4155/fsoa-2018-0012. eCollection 2018 Jul.
AIM
To investigate whether urine levels of miRNAs that regulate the function of endothelial cells are associated with effectiveness in benign prostatic hyperplasia (BPH) patients treated with a phosphodiesterase type 5 inhibitor, tadalafil.
PATIENTS & METHODS: We measured urine levels of three miRNAs (miR-21-5p, miR-126-5p & miR-155-5p) in 55 BPH patients before and after tadalafil administration to understand its effectiveness.
RESULTS
Baseline urine miR-21-5p level was an independent predictor of response to tadalafil in multivariate regression analysis (odds ratio: 0.28; 95% CI: 0.10-0.77; p = 0.014). Receiver operator curve analysis revealed that baseline urine miR-21-5p could serve as a predictor of response (area under curve: 0.85; 95% CI: 0.75-0.95; p < 0.001).
CONCLUSION
Urine miR-21-5p could serve as a biomarker in predicting response of tadalafil for BPH.
目的
研究调节内皮细胞功能的微小RNA（miRNA）尿液水平是否与5型磷酸二酯酶抑制剂他达拉非治疗良性前列腺增生（BPH）患者的疗效相关。
患者与方法
我们在55例BPH患者服用他达拉非前后测量了三种miRNA（miR-21-5p、miR-126-5p和miR-155-5p）的尿液水平，以了解其疗效。
结果
在多变量回归分析中，基线尿液miR-21-5p水平是他达拉非反应的独立预测因子（比值比：0.28；95%置信区间：0.10-0.77；p=0.014）。受试者工作特征曲线分析显示，基线尿液miR-21-5p可作为反应的预测指标（曲线下面积：0.85；95%置信区间：0.75-0.95；p<0.001）。
结论
尿液miR-21-5p可作为预测他达拉非治疗BPH反应的生物标志物。
Zotero 插件